Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
$9.94
$3.49
$10.30
$579.72M2.311.43 million shs1.66 million shs
Liquidia Co. stock logo
LQDA
Liquidia
$13.47
+2.2%
$14.67
$5.71
$16.99
$1.02B0.16936,366 shs177,577 shs
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$18.99
+2.4%
$17.62
$14.51
$22.99
$66.66M0.67,932 shs473 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$3.52
+3.8%
$3.87
$1.79
$5.38
$57.69M0.91147,740 shs19,281 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
0.00%0.00%0.00%0.00%0.00%
Liquidia Co. stock logo
LQDA
Liquidia
-0.83%-3.65%-21.22%+7.59%+89.91%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
-2.43%-2.26%+6.61%-14.56%+12.06%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
+3.04%+5.94%-10.08%+0.89%-31.52%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/AN/AN/AN/AN/A
Liquidia Co. stock logo
LQDA
Liquidia
2.0948 of 5 stars
3.31.00.00.01.94.20.6
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
2.9077 of 5 stars
3.55.00.00.01.80.81.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/A
Liquidia Co. stock logo
LQDA
Liquidia
2.60
Moderate Buy$21.0055.90% Upside
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.00
Buy$7.50113.07% Upside

Current Analyst Ratings

Latest PDEX, APEN, SRTS, and LQDA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
4/1/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
3/14/2024
Liquidia Co. stock logo
LQDA
Liquidia
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $32.00
3/13/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
2/21/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
$76.86M0.00N/AN/A$0.69 per share0.00
Liquidia Co. stock logo
LQDA
Liquidia
$17.49M58.55N/AN/A$0.73 per share18.45
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$46.09M1.45$2.24 per share8.48$8.91 per share2.13
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$24.41M2.36$0.06 per share56.97$2.98 per share1.18

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
-$39.84M-$1.02N/AN/AN/A-51.84%-89.48%-33.76%N/A
Liquidia Co. stock logo
LQDA
Liquidia
-$78.50M-$1.20N/AN/AN/A-448.89%-132.16%-65.35%5/2/2024 (Estimated)
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
$7.07M$0.7525.32N/A5.59%8.97%5.40%5/2/2024 (Estimated)
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$490K$0.03117.37N/A1.99%1.04%0.93%5/9/2024 (Confirmed)

Latest PDEX, APEN, SRTS, and LQDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
-$0.04N/A+$0.04N/AN/AN/A  
3/13/2024Q4 2023
Liquidia Co. stock logo
LQDA
Liquidia
-$0.23-$0.42-$0.19-$0.42$5.29 million$4.53 million
2/8/2024Q2 2024
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/A$0.14+$0.14$0.14N/A$12.59 million
2/8/2024Q4 2023
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.12$0.26+$0.14$0.26$12.10 million$12.57 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
N/AN/AN/AN/AN/A
Liquidia Co. stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
1.04
2.35
1.89
Liquidia Co. stock logo
LQDA
Liquidia
N/A
4.85
4.85
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
0.26
3.66
2.16
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
11.76
8.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
76.01%
Liquidia Co. stock logo
LQDA
Liquidia
64.54%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
15.28%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%

Insider Ownership

CompanyInsider Ownership
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
17.30%
Liquidia Co. stock logo
LQDA
Liquidia
31.60%
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
42.60%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
11.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Apollo Endosurgery, Inc. stock logo
APEN
Apollo Endosurgery
20257.97 million47.94 millionNot Optionable
Liquidia Co. stock logo
LQDA
Liquidia
14576.03 million52.00 millionOptionable
Pro-Dex, Inc. stock logo
PDEX
Pro-Dex
1453.51 million2.02 millionNot Optionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3516.39 million14.57 millionOptionable

PDEX, APEN, SRTS, and LQDA Headlines

SourceHeadline
Sensus Healthcare (NASDAQ:SRTS) Stock Passes Below Fifty Day Moving Average of $3.89Sensus Healthcare (NASDAQ:SRTS) Stock Passes Below Fifty Day Moving Average of $3.89
americanbankingnews.com - April 20 at 4:22 AM
Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024
globenewswire.com - April 18 at 4:05 PM
Sensus Healthcare, Inc. (NASDAQ:SRTS) Sees Large Increase in Short InterestSensus Healthcare, Inc. (NASDAQ:SRTS) Sees Large Increase in Short Interest
marketbeat.com - March 28 at 11:58 AM
Sensus Healthcare Inc.Sensus Healthcare Inc.
wsj.com - March 23 at 2:11 AM
Sensus Healthcare to Participate in the 36th Annual Roth ConferenceSensus Healthcare to Participate in the 36th Annual Roth Conference
globenewswire.com - March 14 at 4:05 PM
Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual MeetingSensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual Meeting
globenewswire.com - March 13 at 8:00 AM
A Market With a HangoverA Market With a Hangover
realmoney.thestreet.com - March 11 at 1:19 PM
3 Stocks to Buy That Are Up 100% or More in 20243 Stocks to Buy That Are Up 100% or More in 2024
investorplace.com - February 25 at 2:02 PM
Sensus Healthcare (SRTS) Price Target Increased by 24.07% to 6.83Sensus Healthcare (SRTS) Price Target Increased by 24.07% to 6.83
msn.com - February 24 at 4:42 AM
Sensus Healthcare Stock (NASDAQ:SRTS) Earnings Dates and Earning CallsSensus Healthcare Stock (NASDAQ:SRTS) Earnings Dates and Earning Calls
benzinga.com - February 23 at 5:28 PM
My Current Game Plan Includes Adding This Small-Cap Stock to My Watch ListMy Current Game Plan Includes Adding This Small-Cap Stock to My Watch List
realmoney.thestreet.com - February 21 at 8:19 PM
Integer Holdings Corporation (ITGR) Soars to 52-Week High, Time to Cash Out?Integer Holdings Corporation (ITGR) Soars to 52-Week High, Time to Cash Out?
finance.yahoo.com - February 12 at 12:53 PM
Sensus Healthcare, Inc. Beat Analyst Profit Forecasts, And Analysts Have New EstimatesSensus Healthcare, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
finance.yahoo.com - February 11 at 10:42 AM
Sensus Healthcare: Strong Q4 Performance and Promising Future Drive Buy RatingSensus Healthcare: Strong Q4 Performance and Promising Future Drive Buy Rating
markets.businessinsider.com - February 10 at 3:48 PM
Sensus Healthcare, Inc. (SRTS) Q4 2023 Earnings Call TranscriptSensus Healthcare, Inc. (SRTS) Q4 2023 Earnings Call Transcript
seekingalpha.com - February 9 at 7:12 PM
Sensus Healthcare, Inc. (NASDAQ:SRTS) Q4 2023 Earnings Call TranscriptSensus Healthcare, Inc. (NASDAQ:SRTS) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 9 at 2:11 PM
Q4 2023 Sensus Healthcare Inc Earnings CallQ4 2023 Sensus Healthcare Inc Earnings Call
finance.yahoo.com - February 9 at 9:10 AM
Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial ResultsSensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results
markets.businessinsider.com - February 8 at 7:56 PM
Sensus Healthcare announces U.S. patent for SRT-100 Vision SystemSensus Healthcare announces U.S. patent for SRT-100 Vision System
msn.com - February 8 at 9:55 AM
Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) CapabilitiesSensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) Capabilities
finance.yahoo.com - February 8 at 9:55 AM
Earnings Preview For Sensus HealthcareEarnings Preview For Sensus Healthcare
benzinga.com - February 7 at 3:46 PM
Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory RequirementsSensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements
finance.yahoo.com - February 6 at 1:04 PM
Sensus Healthcare Announces Director Samuel O’Rear’s RetirementSensus Healthcare Announces Director Samuel O’Rear’s Retirement
msn.com - February 3 at 9:40 AM
Apple, Amazon and Meta Will Tell Us a Lot About This Markets HealthApple, Amazon and Meta Will Tell Us a Lot About This Market's Health
realmoney.thestreet.com - February 2 at 12:48 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Apollo Endosurgery logo

Apollo Endosurgery

NASDAQ:APEN
Apollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.
Liquidia logo

Liquidia

NASDAQ:LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Pro-Dex logo

Pro-Dex

NASDAQ:PDEX
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Sensus Healthcare logo

Sensus Healthcare

NASDAQ:SRTS
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.